Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shift Bioscience Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity involves 1 distinct examiner and 1 distinct art unit, indicating a highly specific area of examination. Christopher M Gross is identified as the busiest examiner for the portfolio, currently handling 1 pending office action. This single matter represents the entirety of the company's active office actions.
The concentration of 1 pending office action under 1 distinct examiner suggests a focused interaction with the patent office. Christopher M Gross, as the busiest examiner, oversees 1 pending office action within the Biotechnology & Pharmaceuticals sector. The presence of only 1 distinct art unit confirms that the company's current filings are not widely distributed across different examination groups. For practitioners, this means the outcome of the portfolio's current activity depends on the specific review of 1 distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579196 | TEMPORAL PROPERTY PREDICTOR | GROSS, CHRISTOPHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579196 | TEMPORAL PROPERTY PREDICTOR | GROSS, CHRISTOPHER M | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579196 | TEMPORAL PROPERTY PREDICTOR | GROSS, CHRISTOPHER M | 1684 | §101§102 | Non-Final OA | — | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShift Bioscience Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christopher M Gross has the most, with 1 of Shift Bioscience Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
